LIVE WEBINAR: Thursday, February 25, 2021, 5:00 PM – 6:30 PM Eastern Time

Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Prostate Cancer (Part 1 of a 3-Part Series)

A CME Webinar Series Held in Conjunction with the 2021 Genitourinary Cancers Symposium

Register Now

Register for either or both the Feb 25 and Mar 4 complimentary events with the “Register Now” button above,
which will take you to our Zoom registration page.

Join us on Thursday, February 25th for this CME-accredited webinar
5:00 PM – 6:30 PM Eastern Time

Faculty

Tanya B Dorff, MD
Associate Clinical Professor of Medicine
City of Hope National Medical Center
Department of Medical Oncology and Developmental Therapeutics
Head, Genitourinary Cancer Program
Los Angeles, California

Fred Saad, MD
Professor and Chief of Urology
Director of GU Oncology
Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
Director, Prostate Cancer Research
Montreal Cancer Institute/CRCHUM
Montréal, Québec



A Oliver Sartor, MD
CE and Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair in Genitourinary Cancers
Professor of Medicine, Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Exelixis Inc, Merck and Sanofi Genzyme.

Not an official event of the 2021 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2021 Genitourinary Cancers Symposium.

Thursday, February 25, 2021
5:00 PM – 6:30 PM Eastern Time
Live CME-accredited webinar

Topics to Be Discussed

  • Management of Nonmetastatic Castration-Resistant Prostate Cancer (CRPC)
  • Therapeutic Options for Patients with Metastatic Hormone-Sensitive Prostate Cancer
  • Integration of PARP Inhibitors into the Management of Metastatic CRPC (mCRPC)
  • Selection and Sequencing of Therapies for mCRPC; Novel Strategies Under Investigation

A detailed agenda will be provided in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Evaluate the published research database supporting the recent FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and apply this information in the recommendation of nonresearch treatment options for patients.
  • Appraise the similarities and differences among commercially available next-generation antiandrogen agents to personalize therapy selection for patients.
  • Recognize the adverse effects associated with hormonal agents commonly used in the management of prostate cancer, and develop strategies to prevent, mitigate and manage these toxicities.
  • Explore available data with cytotoxic and secondary hormonal therapy for hormone-sensitive metastatic prostate cancer to design effective treatment plans for patients.
  • Apply clinical research findings in the determination of best-practice selection and sequencing of available local and systemic treatment modalities for patients with metastatic CRPC.
  • Describe the rationale for testing patients with progressive CRPC for BRCA1/2 or other related mutations, and advise those found to harbor these genetic abnormalities about the FDA approvals and potential benefits of PARP inhibitors.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and counsel appropriate patients about availability and participation.

CME Credit Form
A CME credit form will be emailed to participants within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Dr DorffAdvisory Committee: AbbVie Inc, Advanced Accelerator Applications, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Janssen Biotech Inc; Consulting Agreements: Dendreon Pharmaceuticals Inc, Janssen Biotech Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Pfizer Inc. Dr SaadAdvisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Biotech Inc, Merck, Myovant Sciences, Novartis, Pfizer Inc, Sanofi Genzyme. Dr SartorConsulting Agreements: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bavarian Nordic, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Bristol-Myers Squibb Company, Clarity Pharmaceuticals, Clovis Oncology, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Fusion Pharmaceuticals, ITM Isotopen Technologien Muenchen AG, Janssen Biotech Inc, Myovant Sciences, Myriad Genetic Laboratories Inc, Noria Therapeutics Inc, Novartis, Noxopharm, Pfizer Inc, Point Biopharma Inc, Progenics Pharmaceuticals Inc, Sanofi Genzyme, Telix Pharmaceuticals, TeneoBio, Theragnostics; Contracted Research: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Invitae, Janssen Biotech Inc, Merck, Progenics Pharmaceuticals Inc, Sanofi Genzyme, SOTIO LLC. Dr SmithAdvisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Exelixis Inc, Merck and Sanofi Genzyme.